secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056958
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside reports Q1 net loss $11.8M, $0.17/sh; cash $35.4M; ODYSSEY topline due Q3 2024
--------------------------------------------------------------------------------

- Net loss $11.8M ($0.17/sh) vs $9.3M ($0.15) Q1 2023; revenue $230K up from $4K.
- Cash $35.4M expected to fund operations into Q3 2025.
- Phase 2b ODYSSEY trial of CLS-AX in wet AMD topline data expected Q3 2024.
- Appointed Victor Chong as CMO (March 2024) and Tony Gibney to Board (April 2024).
- Completed $15M registered direct offering in Feb 2024; new CPT code for XIPERE effective Jan 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/0000950170-24-056958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/clsd-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer